scispace - formally typeset
S

Saiba Shams

Publications -  5
Citations -  715

Saiba Shams is an academic researcher. The author has contributed to research in topics: Cancer & Polyunsaturated fatty acid. The author has an hindex of 3, co-authored 4 publications receiving 494 citations.

Papers
More filters
Journal ArticleDOI

Essential oils used in aromatherapy: A systemic review

TL;DR: This review explores the information available in the literature regarding therapeutic, medical, cosmetic, psychological, olfactory, massage aromather therapy, safety issues and different plants used in aromatherapy.
Journal ArticleDOI

In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment.

TL;DR: The present docking study suggests that tea polyphenols inhibit AChE as well as BChE and enhance the cholinergic neurotransmission by prolonging the time and cholinesterase inhibitors are suggested as the standard drugs for the treatment of AD.
Journal ArticleDOI

Antifungal effect of Gatifloxacin and copper ions combination.

TL;DR: Outcomes of the research concluded that gatifloxacin 100 μg ml−1 can be used by 0.20% of copper ions to prevent growth of some fungal strains, which causes skin infections with more potency.
Journal ArticleDOI

In silico analysis for predicting fatty acids of black cumin oil as inhibitors of P-glycoprotein

TL;DR: Generation of 3D structure of fatty acid compounds from Black cumin oil and 3D homology modeling of Rat P glycoprotein as a receptor plays a significant role in finding hot spots in P- gp and may offer the further scope of designing potent and specific inhibitors of P-gp.
Journal ArticleDOI

Nanomedicines: intervention in inflammatory pathways of cancer

TL;DR: In this article , a review on the inflammatory pathways in progression of a tumor, and advancement in nanotechnologies targeting these pathways is presented, and gaps that hinder the successful clinical translation of nanotherapeutics with further clinical studies that will allow oncologist to precisely identify the patients who may be benefited from nanotherapy at time when promotion or progression of tumor initiates.